The European Hematology Association's annual meeting presents the latest news in hematology and its subspecialties with evidence-based approaches to diagnosis and treatment, recent clinical and translational research data, and more.
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
June 25th 2025The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, according to Xavier Leleu, MD, PhD.
Read More
Long-Term Data Support Cilta-Cel Use in R/R Multiple Myeloma: Sundar Jagannath, MBBS
June 25th 2025Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the Icahn School of Medicine at Mount Sinai.
Read More
New Findings Highlight Key Role of Clinician Communication in Lymphoma, CLL Care: Lorna Warwick
June 24th 2025Lorna Warwick, CEO of the Lymphoma Coalition, highlights findings underscoring the vital role of clinician communication in managing adverse effects and supporting patient confidence in lymphoma and chronic lymphocytic leukemia (CLL) care.
Read More
CARTITUDE-4 Data Solidify Cilta-cel’s Role in RRMM: Surbhi Sidana, MD, MBBS
June 19th 2025Surbhi Sidana, MD, MBBS, director of the Myeloma Disease Focused Group at Stanford University, provides a reintroduction to CARTITUDE-4 and insight on how this phase 3 investigation builds on previous findings of CAR T vs standard-of-care findings in relapsed/refractory multiple myeloma (RRMM)
Read More
DVRd vs VRd in Transplant-Ineligible Myeloma: Insights From Saad Z. Usmani, MD, MBA
June 18th 2025CEPHEUS trial lead investigator Saad Z. Usmani, MD, MBA, FACP, FASCO, explains how the trial both builds on current knowledge of newly diagnosed multiple myeloma and how transplant-ineligible status may affect therapeutic decision-making.
Read More
How AI Can Live Up to the Hype in Hematology
June 16th 2025Sessions and posters at the 2025 European Hematology Association Congress evaluated the potential and real-world practices of using artificial intelligence (AI) to predict and improve outcomes for patients with hematological diseases.
Read More
Global Hematology Experts Reflect on Key Takeaways From the EHA 2025 Congress
At the 30th European Hematology Association (EHA) Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.
Read More
Unaddressed Adverse Effects Undermine Patient Confidence in Lymphoma, CLL Care Plans: Lorna Warwick
June 15th 2025Unaddressed adverse effects, such as fatigue, significantly reduce patient confidence in care plans and negatively impact quality of life for individuals with lymphoma and chronic lymphocytic leukemia (CLL), according to Lorna Warwick, CEO of Lymphoma Coalition.
Read More
Beat AML Master Trial Expands Precision Medicine Options for Patients With AML: Ashley Yocum, PhD
June 15th 2025At the European Hematology Association (EHA) 2025 Congress, Ashley Yocum, PhD, highlights how the Beat AML Master Trial advances safe, personalized treatment and expands targeted therapy options for patients with acute myeloid leukemia (AML).
Read More
Discussing Sexuality, Mental Health With AYA Patients Amid the Hematological Treatment Journey
June 14th 2025Adolescent and young adult (AYA) patients with hematological diseases have unique needs that require a multidisciplinary strategy to ensure their mental and sexual well-being during and beyond treatment, clinicians and patients agreed.
Read More
Adding polatuzumab vedotin to rituximab, gemcitabine, and oxaliplatin (R-GemOx) significantly improved overall survival in transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), according to Matthew Matasar, MD, of Rutgers Cancer institute.
Read More
Phase 3 IRAKLIA Trial Compares On-Body vs IV Isatuximab in RRMM: Xavier Leleu, MD, PhD
June 14th 2025The phase 3 IRAKLIA trial assesses subcutaneous isatuximab via on-body injector vs intravenous (IV) administration, in combination with pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (RRMM).
Read More
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
Early results from the phase 1 SANRECO trial suggest that divesiran is safe and well tolerated, and may reduce the need for phlebotomy in patients with polycythemia vera by increasing hepcidin levels and improving iron regulation, according to lead investigator Marina Kremyanskaya, MD, PhD.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
Fighting Burnout in Hematology Through Awareness, Balance: Adela Perolla, MD, PhD
June 12th 2025In this clip, Adela Perolla, MD, PhD, discusses the urgent need to address and destigmatize burnout in hematology, especially among early-career professionals, by promoting self-awareness, work-life balance, and peer support.
Read More